Improving biophysical properties of a bispecific antibody scaffold to aid developability: Quality by molecular design

mAbs

Volumn 5, Issue 5, 2013, Pages 646-654

  Kreudenstein, Thomas Spreter Von ^a   Escobar Carbrera, Eric ^a   Lario, Paula I ^a   D'Angelo, Igor ^a   Brault, Karine ^b   Kelly, John ^b   Durocher, Yves ^b   Baardsnes, Jason ^b   Jeremy Woods, R ^c   Xie, Michael Hongwei ^c   Girod, Pierre Alain ^d   Suits, Michael D L ^e   Boulanger, Martin J ^e   Poon, David K Y ^a   Ng, Gordon Y K ^a   Dixit, Surjit B ^a  

^a Zymeworks Inc   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c KBI Biopharma Inc   (United States)

^d Selexis   (Switzerland)

^e UNIVERSITY OF VICTORIA   (Canada)

Author keywords

Antibody engineering; Antibody stability; Biophysical characterization of antibody; Bispecific antibody; Fc engineering; Heterodimeric antibody; LC MS of antibody; Quality by design

Indexed keywords

BISPECIFIC ANTIBODY; HOMODIMER; MOLECULAR SCAFFOLD; TRASTUZUMAB;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG PURITY; DRUG STABILITY; MACACA FASCICULARIS; MUTATION; NONHUMAN; PREFORMULATION; PROTEIN DOMAIN; PROTEIN ENGINEERING; QUALITATIVE ANALYSIS;

ANTIBODY ENGINEERING; ANTIBODY STABILITY; BIOPHYSICAL CHARACTERIZATION OF ANTIBODY; BISPECIFIC ANTIBODY; FC ENGINEERING; HETERODIMERIC ANTIBODY; LC-MS OF ANTIBODY; QUALITY BY DESIGN;

ANIMALS; ANTIBODIES; ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; CHO CELLS; CHROMATOGRAPHY, LIQUID; CRICETINAE; CRICETULUS; DRUG DESIGN; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMMUNOGLOBULIN FC FRAGMENTS; MASS SPECTROMETRY; MODELS, MOLECULAR; MUTATION; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; STATIC ELECTRICITY; TEMPERATURE;

EID: 84883876685     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.25632     Document Type: Article

References (52)

1. Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4:182-97; PMID:22453100; http://dx.doi.org/10.4161/mabs.4.2.19000
2. Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 2011; 317:1261-9; PMID:21371474; http://dx.doi.org/10.1016/j.yexcr.2011.02.013
3. Segal DM, Weiner GJ, Weiner LM. Introduction: bispecific antibodies. J Immunol Methods 2001; 248:1-6; PMID:11223064; http://dx.doi.org/10.1016/S0022- 1759(00)00338-0
4. Carter P. Bispecific human IgG by design. J Immunol Methods 2001; 248:7-15; PMID:11223065; http://dx.doi.org/10.1016/S0022-1759(00)00339-2
5. Swann PG, Tolnay M, Muthukkumar S, Shapiro MA, Rellahan BL, Clouse KA. Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol 2008; 20:493-9; PMID:18586093; http://dx.doi.org/10.1016/j.coi. 2008.05.013
6. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/protein/9.7.617
7. Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997; 270:26-35; PMID:9231898; http://dx.doi. org/10.1006/jmbi.1997. 1116
8. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677-81; PMID:9661204; http://dx.doi.org/10.1038/nbt0798-677
9. Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18:1570-4; PMID:23023498; http://dx.doi.org/10.1038/nm.2942
10. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011; 3:84ra44; PMID:21613623; http://dx.doi. org/10.1126/scitranslmed.3002230
11. Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-92; PMID:21690412; http://dx.doi. org/10.1073/pnas.1019002108
12. Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, et al. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 2012; 4:653-63; PMID:22925968; http://dx.doi.org/10.4161/mabs.21379
13. Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68:4360-8; PMID:18519697; http://dx.doi. org/10.1158/0008-5472.CAN-07-5960
14. Klein C, Schaefer W. Bivalent, bispecific antibodies. USPTO. US2009/023811A1, 2009:para 268.
15. Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, et al. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 2010; 285:20850-9; PMID:20444694; http://dx.doi. org/10.1074/jbc.M110.113910
16. Wranik BJ, Christensen EL, Schaefer G, Jackman JK, Vendel AC, Eaton D. LUZ-Y, a novel platform for the mammalian cell production of full-length IgGbispecific antibodies. J Biol Chem 2012; 287:43331-9; PMID:23118228; http://dx.doi.org/10.1074/jbc. M112.397869
17. Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 2012; 420:204-19; PMID:22543237; http://dx.doi.org/10.1016/j.jmb.2012. 04.020
18. Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 2013; 110:5145-50; PMID:23479652; http://dx.doi.org/10.1073/pnas.1220145110
19. Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285:19637-46; PMID:20400508; http://dx.doi.org/10.1074/jbc. M110.117382
20. Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, et al. SEEDbodies: fusion proteins based on strandexchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23:195-202; PMID:20299542; http://dx.doi.org/10.1093/protein/gzp094
21. Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 2011; 3:546-57; PMID:22123055; http://dx.doi. org/10.4161/mabs.3.6.18123
22. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 2005; 289:1-30; PMID:15652195; http://dx.doi.org/10.1016/j. ijpharm.2004.11.014
23. Demarest SJ, Glaser SM. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 2008; 11:675-87; PMID:18729019
24. Wen J, Jiang Y, Hymes K, Gong K, Nahri L. Using Differential Scanning Calorimetry in Understanding the Correlation Between Thermal Stability and Protein Stability: A Case Study. Microcal Application Note, 2011.
25. Liu H, May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs 2012; 4:17-23; PMID:22327427; http://dx.doi.org/10. 4161/mabs.4.1.18347
26. Yang X, Xu W, Dukleska S, Benchaar B, Mengisen S, Antochshuk V, et al. Developability studies before initiation of process development: Improving manufacturability of monoclonal antibodies. MAbs 2013; 5:787-94; http://dx.doi.org/10.4161/mabs.25269.
27. Buchanan A, Clementel V, Woods R, Harn N, Bowen MA, Mo W, et al. Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression. MAbs 2013; 5:255-62; PMID:23412563; http://dx.doi. org/10.4161/mabs.23392
28. Bolon DN, Grant RA, Baker TA, Sauer RT. Specificity versus stability in computational protein design. Proc Natl Acad Sci U S A 2005; 102:12724-9; PMID:16129838; http://dx.doi.org/10.1073/pnas.0506124102
29. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 1981; 20:2361-70; PMID:7236608; http://dx.doi. org/10.1021/bi00512a001
30. Dall'Acqua W, Simon AL, Mulkerrin MG, Carter P. Contribution of domain interface residues to the stability of antibody CH3 domain homodimers. Biochemistry 1998; 37:9266-73; PMID:9649307; http://dx.doi.org/10.1021/bi980270i
31. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 2006; 65:712-25; PMID:16981200; http://dx.doi.org/10.1002/prot.21123
32. Jayaram B, Sprous D, Beveridge DL. Solvation Free Energy of Biomacromolecules: Parameters for a Modified Generalized Born Model Consistent with the AMBER Force Field. J Phys Chem B 1998; 102:9571-6; http://dx.doi.org/ 10.1021/jp982007x
33. Vajda S, Sippl M, Novotny J. Empirical potentials and functions for protein folding and binding. Curr Opin Struct Biol 1997; 7:222-8; PMID:9094333; http://dx.doi.org/10.1016/S0959-440X(97)80029-2
34. Xiang Z, Honig B. Extending the accuracy limits of prediction for side-chain conformations. J Mol Biol 2001; 311:421-30; PMID:11478870; http://dx.doi. org/10.1006/jmbi.2001.4865
35. rd, Richardson DC, Richardson JS. The backrub motion: how protein backbone shrugs when a sidechain dances. Structure 2006; 14:265-74; PMID:16472746; http://dx.doi. org/10.1016/j.str.2005.10.007
36. De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 2009; 131:189-201; PMID:19269256; http://dx.doi.org/10.1016/j. clim.2009.01.009
37. Bryson CJ, Jones TD, Baker MP. Prediction of immunogenicity of therapeutic proteins: validity of computational tools. Bio Drugs 2010; 24:1-8; PMID:20055528; http://dx.doi.org/10.2165/11318560-000000000-00000
38. Ionescu RM, Vlasak J, Price C, Kirchmeier M. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 2008; 97:1414-26; PMID:17721938; http://dx.doi. org/10.1002/jps.21104
39. Li CH, Narhi LO, Wen J, Dimitrova M, Wen ZQ, Li J, et al. Effect of pH, temperature, and salt on the stability of Escherichia coli- and Chinese hamster ovary cell-derived IgG1 Fc. Biochemistry 2012; 51:10056-65; PMID:23078371; http://dx.doi.org/10.1021/bi300702e
40. Demarest SJ, Rogers J, Hansen G. Optimization of the antibody C(H)3 domain by residue frequency analysis of IgG sequences. J Mol Biol 2004; 335:41-8; PMID:14659738; http://dx.doi.org/10.1016/j. jmb.2003.10.040
41. Garber E, Demarest SJ. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun 2007; 355:751-7; PMID:17321501; http://dx.doi.org/10.1016/j.bbrc.2007.02.042
42. Feige MJ, Walter S, Buchner J. Folding mechanism of the CH2 antibody domain. J Mol Biol 2004; 344:107-18; PMID:15504405; http://dx.doi.org/10.1016/j. jmb.2004.09.033
43. Thies MJ, Mayer J, Augustine JG, Frederick CA, Lilie H, Buchner J. Folding and association of the antibody domain CH3: prolyl isomerization preceeds dimerization. J Mol Biol 1999; 293:67-79; PMID:10512716; http://dx.doi.org/10.1006/jmbi.1999.3128
44. Thies MJ, Talamo F, Mayer M, Bell S, Ruoppolo M, Marino G, et al. Folding and oxidation of the antibody domain C(H)3. J Mol Biol 2002; 319:1267-77; PMID:12079363; http://dx.doi.org/10.1016/S0022-2836(02)00375-3
45. McAuley A, Jacob J, Kolvenbach CG, Westland K, Lee HJ, Brych SR, et al. Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain. Protein Sci 2008; 17:95-106; PMID:18156469; http://dx.doi.org/10.1110/ps.073134408
46. Reichert JM. Bispecific antibodies and ADCs: Once and future kings? MAbs 2011; 3:329-30; PMID:21654205; http://dx.doi.org/10.4161/mabs.3.4.16589
47. Wakankar AA, Feeney MB, Rivera J, Chen Y, Kim M, Sharma VK, et al. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. Bioconjug Chem 2010; 21:1588-95; PMID:20698491; http://dx.doi.org/10.1021/bc900434c
48. Hawe A, Wiggenhorn M, van de Weert M, Garbe JH, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci 2012; 101:895-913; PMID:22083792; http://dx.doi.org/10.1002/jps.22812
49. Raibekas AA. Estimation of protein aggregation propensity with a melting point apparatus. Anal Biochem 2008; 380:331-2; PMID:18544334; http://dx.doi. org/10.1016/j.ab.2008.05.023
50. Woods RJ, Xie M, von Kreudenstein T, Ng G, Dixit SB. LC-MS characterization and purity assessment of a prototype bispecific antibody. MAbs 2013; 5:711-22; http://dx.doi.org/10.4161/mabs.25488.
51. Girod PA, Le Fourn V. Rapid production of functional proteins of a combinatorial IgG library in CHO cells. Bioprocess Int 2012; 10:58-61
52. Serpieri F, Inocencio A, de Oliveira JM, Pimenta AA Jr., Garbuio A, Kalil J, et al. Comparison of humanized IgG and FvFc anti-CD3 monoclonal antibodies expressed in CHO cells. Mol Biotechnol 2010; 45:218-25; PMID:20336495; http://dx.doi.org/10.1007/s12033-010-9269-2